Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-12-28

FDA Approved: AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL — Supplemental Application (Alembic Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application to allow Alembic Pharmaceuticals to market a generic fixed-dose combination of amlodipine besylate and olmesartan me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine Besylate and Olmesartan Medoxomil (amlodipine besylate and olmesartan medoxomil)

Snippet

SUPPL AP for AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL (AMLODIPINE BESYLATE AND OLMESARTRAN MEDOXOMIL)